Anifrolumab, a relatively recent monoclonal antigen, is creating considerable hope within the healthcare community as a possible therapy for various immune-related disorders. This innovative agent targets the https://prbookmarkingwebsites.com/story28773329/anifrolumab-a-new-approach-for-self-reactive-diseases